The promise of chimeric antigen receptor engineered T cells in the treatment of hematologic malignancies

Cancer Journal (United States)

Volumn 22, Issue 1, 2016, Pages 27-33

  Nagle, Sarah J ^a   Garfall, Alfred L ^a   Stadtmauer, Edward A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Acute lymphoblastic leukemia (ALL); acute myeloid leukemia (AML); chimeric antigen receptor (CAR) T cells; chronic lymphocytic leukemia (CLL); hematologic malignancies; Hodgkin lymphoma (HL); multiple myeloma (MM); non Hodgkin lymphoma (NHL); therapies

Indexed keywords

B CELL MATURATION ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; RETROVIRUS VECTOR; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOPTIVE TRANSFER; APLASIA; B LYMPHOCYTE APLASIA; CELL ENGINEERING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); CYTOKINE RELEASE SYNDROME; DRUG DESIGN; DRUG MANUFACTURE; DRUG USE; EX VIVO STUDY; GENE TRANSFER; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; MULTIPLE MYELOMA; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; ADOPTIVE IMMUNOTHERAPY; ADVERSE EFFECTS; ANIMAL; BIOLOGICAL THERAPY; GENE THERAPY; GENETICS; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; METABOLISM; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; ANTIGENS, NEOPLASM; CELL- AND TISSUE-BASED THERAPY; GENETIC THERAPY; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84957624502     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000166     Document Type: Review

References (72)

1. Lamers CH, Sleijfer S, Vulto AG, Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol. 2006; 24 (13): e20-2.
2. Morgan RA, Yang JC, Kitano M, Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010; 18: 843-851.
3. Eshhar Z, Waks T, Bendavid A, Functional expression of chimeric receptor genes in human T cells. J Immunol Methods. 2001; 248: 67-76.
4. Hombach A, Heuser C, Gerken M, T cell activation by recombinant FcepsilonRI gamma-chain immune receptors: an extracellular spacer domain impairs antigen-dependent T cell activation but not antigen recognition. Gene Ther. 2000; 7: 1067-1075.
5. Hombach A, Hombach AA, Abken H,. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 f. 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response. Gene Ther. 2010; 17: 1206-1213.
6. Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res. 2013; 19: 3153-3164.
7. Savoldo B, Ramos CA, Liu E, CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011; 121: 1822-1826.
8. Maher J, Brentjens RJ, Gunset G, Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol. 2002; 20: 70-75.
9. Morgan RA, Kakarla S,. Genetic modification of T cells. Cancer J. 2014; 20: 145-150.
10. Modlich U, Navarro S, Zychlinski D, Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther. 2009; 17: 1919-1928.
11. Hackett PB, Largaespada DA, Cooper LJ,. A transposon and transposase system for human application. Mol Ther. 2010; 18: 674-683.
12. Singh H, Manuri PR, Olivares S, Redirecting specificity of T-cell populations for CD19 using the sleeping beauty system. Cancer Res. 2008; 68: 2961-2971.
13. Maiti SN, Huls H, Singh H, Sleeping beauty system to redirect T-cell specificity for human applications. J Immunother. 2013; 36: 112-123.
14. Barrett DM, Zhao Y, Liu X, Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther. 2011; 22: 1575-1586.
15. + T cells for use in the adoptive immunotherapy of cancer. Gene Ther. 2009; 16: 596-604.
16. Zhao Y, Zheng Z, Cohen CJ, High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol Ther. 2006; 13: 151-159.
17. + T cells for adoptive immunotherapy. Blood. 2008; 111: 5326-5333.
18. Hollyman D, Stefanski J, Przybylowski M, Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother. 2009; 32: 169-180.
19. Johnson LA, Morgan RA, Dudley ME, Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009; 114: 535-546.
20. Maus MV, Thomas AK, Leonard DG, Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol. 2002; 20: 143-148.
21. Jensen MC, Popplewell L, Cooper LJ, Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant. 2010; 16: 1245-1256.
22. Porter DL, Levine BL, Bunin N, A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood. 2006; 107: 1325-1331.
23. Kochenderfer JN, Dudley ME, Feldman SA, B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012; 119: 2709-2720.
24. Brentjens RJ, Rivière I, Park JH, Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011; 118: 4817-4828.
25. Singh H, Figliola MJ, Dawson MJ, Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res. 2011; 71: 3516-3527.
26. Porter DL, Levine BL, Kalos M, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365: 725-733.
27. Jensen MC, Clarke P, Tan G, Human T lymphocyte genetic modification with naked DNA. Mol Ther. 2000; 1: 49-55.
28. Ye Q, Loisiou M, Levine BL, Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes. J Transl Med. 2011; 9: 131-5876-9-131.
29. Kochenderfer JN, Yu Z, Frasheri D, Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood. 2010; 116: 3875-3886.
30. Rosenberg SA, Yang JC, Sherry RM, Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011; 17: 4550-4557.
31. Restifo NP, Dudley ME, Rosenberg SA,. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012; 12: 269-281.
32. + T helper cells and hindered by naturally occurring T regulatory cells. J Immunol. 2005; 174: 2591-2601.
33. + T cells. J Exp Med. 2005; 202: 907-912.
34. Kershaw MH, Westwood JA, Parker LL, A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006; 12 (20 pt 1): 6106-6115.
35. Ritchie DS, Neeson PJ, Khot A, Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther. 2013; 21: 2122-2129.
36. Parente-Pereira AC, Burnet J, Ellison D, Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice. J Clin Immunol. 2011; 31: 710-718.
37. Kalos M, Levine BL, Porter DL, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011; 3: 95ra73.
38. Kochenderfer JN, Dudley ME, Kassim SH, Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015; 33: 540-549.
39. Schuster SJ, Svoboda J, Nasta SD, Oral presentations: phase II trial of chimeric antigen receptor modified T cells directed against CD19 in relapsed/refractory diffuse large B cell, follicular, and mantle cell lymphomas. Hematol Oncol. 2015; 33: 175-176.
40. Porter DL, Hwang WT, Frey NV, Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015; 7: 303ra139.
41. Sauter CS, Riviere I, Bernal Y, Phase I trial of 19-28z chimeric antigen receptor modified T cells (19-28z CAR-T) post-high dose therapy and autologous stem cell transplant (HDT-ASCT) for relapsed and refractory (rel/ref) aggressive B-cell non-Hodgkin lymphoma (B-NHL). ASCO Meeting Abstracts. 2015; 33: 8515.
42. + B-cells for relapsed and refractory aggressive B cell non-Hodgkin lymphoma (B-NHL). Blood. 2014; 124: 677-677.
43. Fielding AK, Richards SM, Chopra R, Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007; 109: 944-950.
44. Brentjens RJ, Davila ML, Riviere I, CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013; 5: 177ra38.
45. Grupp SA, Kalos M, Barrett D, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013; 368: 1509-1518.
46. Maude SL, Frey N, Shaw PA, Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371: 1507-1517.
47. Davila ML, Riviere I, Wang X, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014; 6: 224ra25.
48. Lee DW, Kochenderfer JN, Stetler-Stevenson M, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015; 385: 517-528.
49. Yuriev E, Farrugia W, Scott AM, Three-dimensional structures of carbohydrate determinants of lewis system antigens: implications for effective antibody targeting of cancer. Immunol Cell Biol. 2005; 83: 709-717.
50. Zhang T, Lemoi BA, Sentman CL,. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood. 2005; 106: 1544-1551.
51. Zhang T, Barber A, Sentman CL,. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Cancer Res. 2006; 66: 5927-5933.
52. Zhang T, Barber A, Sentman CL,. Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways. Cancer Res. 2007; 67: 11029-11036.
53. Barber A, Zhang T, DeMars LR, Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. Cancer Res. 2007; 67: 5003-5008.
54. Barber A, Meehan KR, Sentman CL,. Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells. Gene Ther. 2011; 18: 509-516.
55. Barber A, Zhang T, Megli CJ, Wu J, Meehan KR, Sentman CL,. Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma. Exp Hematol. 2008; 36: 1318-1328.
56. VanSeggelen H, Hammill JA, Dvorkin-Gheva A, T cells engineered with chimeric antigen receptors targeting NKG2D ligands display lethal toxicity in mice. Mol Ther. 2015.
57. Gill S, Tasian SK, Ruella M, Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood. 2014; 123: 2343-2354.
58. Kenderian SS, Ruella M, Shestova O, CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia. 2015; 29: 1637-1647.
59. Wang QS, Wang Y, Lv HY, Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther. 2015; 23: 184-191.
60. Garfall AL, Fraietta JA, Maus MV,. Immunotherapy with chimeric antigen receptors for multiple myeloma. Discov Med. 2014; 17: 37-46.
61. Carpenter RO, Evbuomwan MO, Pittaluga S, B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013; 19: 2048-2060.
62. Hsi ED, Steinle R, Balasa B, CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008; 14: 2775-2784.
63. Chu J, Deng Y, Benson DM, CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia. 2014; 28: 917-927.
64. Chu J, He S, Deng Y, Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells. Clin Cancer Res. 2014; 20: 3989-4000.
65. Garfall AL, Maus MV, Hwang WT, Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med. 2015; 373: 1040-1047.
66. Hajek R, Okubote SA, Svachova H,. Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma. Br J Haematol. 2013; 163: 551-564.
67. Hombach A, Heuser C, Sircar R, Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen. J Immunother. 1999; 22: 473-480.
68. Savoldo B, Rooney CM, Di Stasi A, Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007; 110: 2620-2630.
69. Ruella M, Kenderian SS, Shestova O, Novel chimeric antigen receptor T cells for the treatment of Hodgkin lymphoma. Blood. 2014; 124: 806-806.
70. Cameron BJ, Gerry AB, Dukes J, Identification of a titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med. 2013; 5: 197ra103.
71. Linette GP, Stadtmauer EA, Maus MV, Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013; 122: 863-871.
72. Topp MS, Gökbuget N, Stein AS, Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015; 16: 57-66.